137 related articles for article (PubMed ID: 30415240)
1. The role of purinergic P2Y
Korybalska K; Rutkowski R; Luczak J; Czepulis N; Karpinski K; Witowski J
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30415240
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor and clopidogrel suppress NF-κB signaling pathway to alleviate LPS-induced dysfunction in vein endothelial cells.
Jia Z; Huang Y; Ji X; Sun J; Fu G
BMC Cardiovasc Disord; 2019 Dec; 19(1):318. PubMed ID: 31888640
[TBL] [Abstract][Full Text] [Related]
3. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Reiner MF; Akhmedov A; Stivala S; Keller S; Gaul DS; Bonetti NR; Savarese G; Glanzmann M; Zhu C; Ruf W; Yang Z; Matter CM; Lüscher TF; Camici GG; Beer JH
Cardiovasc Res; 2017 Jan; 113(1):61-69. PubMed ID: 28028070
[TBL] [Abstract][Full Text] [Related]
4. Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options.
Trenk D; Hille L; Leggewie S; Stratz C; Nührenberg TG; Aradi D; Schrör K; Sibbing D
Thromb Haemost; 2019 Oct; 119(10):1606-1616. PubMed ID: 31408901
[TBL] [Abstract][Full Text] [Related]
5. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
Judge HM; Buckland RJ; Jakubowski JA; Storey RF
Platelets; 2016; 27(3):191-5. PubMed ID: 26270719
[TBL] [Abstract][Full Text] [Related]
6. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
[TBL] [Abstract][Full Text] [Related]
7. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
[TBL] [Abstract][Full Text] [Related]
9. Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
Wadowski PP; Kopp CW; Koppensteiner R; Lang IM; Pultar J; Lee S; Weikert C; Panzer S; Gremmel T
Eur J Clin Invest; 2018 Jan; 48(1):. PubMed ID: 29171876
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
11. The role of platelet P2Y
Parker WAE; Storey RF
Br J Pharmacol; 2024 Feb; 181(4):515-531. PubMed ID: 37771103
[TBL] [Abstract][Full Text] [Related]
12. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
Gareau AJ; Brien C; Gebremeskel S; Liwski RS; Johnston B; Bezuhly M
Clin Exp Metastasis; 2018 Feb; 35(1-2):25-35. PubMed ID: 29322294
[TBL] [Abstract][Full Text] [Related]
14. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
15. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
16. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
17. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
Collet JP; O'Connor S
Fundam Clin Pharmacol; 2012 Feb; 26(1):16-8. PubMed ID: 21895760
[TBL] [Abstract][Full Text] [Related]
19. Contemporary use of P2Y
Rakowski T; Siudak Z; Dziewierz A; Plens K; Kleczyński P; Dudek D
J Thromb Thrombolysis; 2018 Jan; 45(1):151-157. PubMed ID: 29075924
[TBL] [Abstract][Full Text] [Related]
20. [Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Gratsianskiĭ NA
Kardiologiia; 2010; 50(6):4-21. PubMed ID: 20659022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]